Le Lézard
Classified in: Sports and recreation, Covid-19 virus

BLUE JAYS 2022 POSTSEASON MEDIA CREDENTIAL INFORMATION


Media applications for the potential Wild Card and American League Division Series at Rogers Centre are now open

TORONTO, Sept. 29, 2022 /CNW/ - The Toronto Blue Jays are headed to the postseason! Media credential applications for the potential Wild Card and American League Division Series (ALDS) at Rogers Centre are now open at credentials.mlb.com under the Toronto Blue Jays page.

Please read the below information carefully as requirements are unique for each round.

Requirements

Potential Wild Card Series at Rogers Centre

Potential ALDS games at Rogers Centre

Potential ALCS and World Series games at Rogers Centre 

SOURCE Toronto Blue Jays


These press releases may also interest you

at 07:05
LiveWire Group, Inc. ("LiveWire" or the "Company") today reported first quarter 2024 results. "We are pleased with the successful launch of the S2 Mulholland, and with three bikes in market, we are proud that LiveWire is now the #1 on-road...

at 07:05
Newmont Corporation (Newmont or the Company) today announced first quarter 2024 results and declared a first quarter dividend of $0.25 per share. "Newmont delivered a strong first quarter operational performance, producing 2.2 million gold...

at 07:05
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine...

at 07:03
Key takeaways Projected return on investment in pharma research and development (R&D) in 2023 has risen to 4.1%, climbing back from 2022's record low of 1.2%.The leading 20 global pharmaceutical companies collectively spent $145 billion on R&D in...

at 07:00
Harley-Davidson, Inc. ("Harley-Davidson," "HDI," or the "Company")  today reported first quarter 2024 results. "Harley-Davidson delivered a good start to the year with a six percent retail growth in North America, our largest and most important...

at 07:00
Moderna, Inc. today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial...



News published on and distributed by: